Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 11/20 | 0.53 |
| ▸ | MAOB | P27338 | 4/20 | 0.47 |
| ▸ | MAOA | P21397 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | CALML3 | P27482 | 1/20 | 0.47 |
| ▸ | SDHA | P31040 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6249323 | 0.89 | F10 (0.56) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL4883262 | 0.88 | F10 (0.50) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL14197116 | 0.88 | F10 (0.50) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL6402337 | 0.88 | MAOA (0.61) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL6402339 | 0.88 | MAOA (0.61) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL5739519 | 0.88 | MAOA (0.48) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL6398185 | 0.87 | F10 (0.55) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL6398188 | 0.87 | F10 (0.55) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL6704404 | 0.87 | F10 (0.49) | F10MAOB | |
| SCHEMBL2949084 | 0.86 | F10 (0.69) | F10MAOBMAOALMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040072842-A1 | Difluorothioacetamides of oxazolidinones with a glycoloylpiperazine substituent | PHARMACIA & UPJOHN COMPANY | 2004-04-15 | — | — | US | claimed |
| EP-1519722-A1 | GLYCOLOYL-SUBSTITUTED OXAZOLIDINONE-DERIVATIVES AS ANTIBACTERIAL AGENTS | Pharmacia & Upjohn Company LLC (US) | 2005-04-06 | — | — | EP | disclosed |
| US-20040072842-A1 | Difluorothioacetamides of oxazolidinones with a glycoloylpiperazine substituent | PHARMACIA & UPJOHN COMPANY | 2004-04-15 | — | — | US | disclosed |
| WO-2004002479-A1 | GLYCOLOYL-SUBSTITUTED OXAZOLIDINONE-DERIVATIVES AS ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072842-A1 | Difluorothioacetamides of oxazolidinones with a glycoloylpiperazine substituent | GMDS, PGLS, DDOST | F10 4107/4885MAOB 3566/4885MAOA 3409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.